| Literature DB >> 28687063 |
Afagh Alavi1, Sara Esmaeili1, Yalda Nilipour2, Shahriar Nafissi3, Seyed Hasan Tonekaboni4, Gholamreza Zamani5, Mahmoud Reza Ashrafi6, Kimia Kahrizi1, Hossein Najmabadi1, Fatemeh Jazayeri3.
Abstract
Sarcoglycanopathies (SGCs) which are caused by mutations in SGCA, SGCB, SGCG or SGCD genes are a subgroup of autosomal-recessive limb-girdle-muscular-dystrophies (LGMD2). Although frequencies of mutations in these genes are different among populations, mutations in SGCA and SGCD, respectively, have the highest and lowest frequencies in most populations. Here, we report the proportion of mutations in SGC genes among a group of Iranian SGCs patients. Clinical features and results of SGC genes screening of 25 SGCs probands are presented. Large deletion mutations are confirmed with MLPA assays. In total, 15 candidate disease causing mutations were observed in the SGCA, SGCB, SGCG and SGCD genes; ten were novel. Fourteen (56%), seven (28%), three (12%) and one (4%) patient, respectively, carried mutations in SGCB, SGCG, SGCD and SGCA. The findings suggest that LGMD2E is the most common form of SGCs in the Iranian population and that LGMD2D is the rarest. Twelve LGMD2E cases carried the same mutation. To the best of knowledge, the mutation spectrum in SGCs is being reported for the first time in Iranian population. The finding will be beneficial for screening and genetic-counseling of SGCs patients in Iran.Entities:
Keywords: SGCA; SGCB; SGCD; SGCG; Sarcoglycanopathy
Mesh:
Year: 2017 PMID: 28687063 DOI: 10.1080/01677063.2017.1346093
Source DB: PubMed Journal: J Neurogenet ISSN: 0167-7063 Impact factor: 1.250